ATTR amyloidosis is a frequently unrecognized but increasingly important cause of cardiomyopathy and neuropathy. While relatively uncommon compared to other etiologies, identification of ATTR in earlier stage of disease is critical to permit available therapies the best efficacy. Despite its importance, a general consensus regarding the most practical approaches toward screening of at-risk patients for ATTR amyloidosis is lacking.
This workshop will address controversies regarding screening for ATTR amyloidosis, particularly relevant to internists, neurologists, and cardiologists. Best practices for screening will be suggested. Following three recorded presentations, a live, 15-minute, moderated discussion will be held to answer viewers submitted questions.
When:
Thursday, July 22, 2021
9 AM EDT (timezone converter)
Registration Linkexternal link, opens in a new tab
This event has ended.